<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Cancer Sciences</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/47E9DF20-943A-4ACF-BB92-A7B049380D29"><gtr:id>47E9DF20-943A-4ACF-BB92-A7B049380D29</gtr:id><gtr:firstName>Yuen</gtr:firstName><gtr:otherNames>Ling</gtr:otherNames><gtr:surname>Chan</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G110379"><gtr:id>ED63ACD7-8698-4AAE-9E9E-B760FFB1E493</gtr:id><gtr:title>Study of the role of polymorphisms within KIR and HLA-C in the immune control of Cytomegalovirus infection</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G110379</gtr:grantReference><gtr:abstractText>The immune system is mediated by the action of white cells in blood which kill cells infected by viruses. The recognition of virally-infected cells depends on a large number of proteins on the white cells and many of these are very variable between different individuals. This variation has probably occurred as it offers better protection for populations in response to infection but it is now clear that this genetic variation in a family of proteins called KIR can have a big influence on the progress of diseases such as infection and auto-immune disease.
Cytomegalovirus is a very common viral infection and studies from bone marrow transplant patients has shown that the KIR genes determine the chance that CMV infection will reactivate when patients have a weakened immune system.
Here we will determine how a persons KIR gene profile determines how they handle chronic infection with CMV. In particular we will establish if they help to prevent infection, whether they alter the size and nature of the immune response to established infection and also how they exert their effects using laboratory and clinical models. This work will be of significant value in understanding the biological role of this important gene family.</gtr:abstractText><gtr:technicalSummary>KIR and HLA interactions mediate important inhibitory and activatory signals to cytotoxic cells within the immune system. Interestingly, the KIR and HLA-C genes are amongst the most polymorphic within the human genome and this has been correlated with the clinical outcome of a wide range of human diseases. However, the mechanisms that have driven this diversity, and its functional significance, remain unclear. Cytomegalovirus (CMV) is a common chronic infection and considerable evidence suggests that KIR &amp;amp; HLA-C polymorphism may influence immune control. In particular infection is less common in HLA-C2 patients in some ethnic groups; CMV reactivation in transplant patients is related to KIR and HLA-C genotype, and mouse CMV proteins have been shown to interact directly with NK immune receptors. 
The aims of the study are to:-
- determine if HLA-C or KIR genotype plays a role in protection against primary CMV infection.
- understand how HLA-C and KIR genotype modulates the quality of the immune response to CMV in chronically infected individuals.
- study the functional implications of such polymorphism on NK and T cell recognition of CMV using both in vitro and in vivo analysis.

The objective is to use the analysis to increase understanding of the biology of the human KIR-HLA-C interaction for future translational application.
The design of the study will comprise an epidemiological analysis of KIR and HLA-C genotype in relation to CMV infection status and assessment of how genotype can influence the magnitude and phenotype of the CMV-specific immune response in chronic infection. Finally, we will determine how the function of CMV-specific effector cells is modulated by KIR-HLA interactions both using established in vitro analyses on infected cells as well as in vivo analysis of the immune response in stem cell transplant patients undergoing episodes of CMV reactivation.
Methodology will comprise detailed assessment of the magnitude, function and phenotype of the cellular and humoral CMV-specific immune response, genotypic assessment of the KIR and HLA genes and statistical analysis of data sets. 
The scientific opportunities include assessment of the mechanisms by which KIR and HLA-C interactions contribute to the control of one of the most common and immunodominant human infections. Medical opportunities will arise from an understanding of how KIR interactions can serve to regulate human immune responses and how this may be manipulated in infectious, auto-immune and malignant disease.</gtr:technicalSummary><gtr:fund><gtr:end>2017-04-03</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-01-04</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>191887</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>339B49E4-D913-41CD-BC66-3375C8F39EC4</gtr:id><gtr:title>NK cells produce high levels of IL-10 early after allogeneic stem cell transplantation and suppress development of acute GVHD.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3a137c0f1a4ef03e78d61ea0389ea85"><gtr:id>e3a137c0f1a4ef03e78d61ea0389ea85</gtr:id><gtr:otherNames>Chan YLT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>5aa04adc79e060.58488530</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A232FE94-08E5-4610-A8B4-D262F76C42C0</gtr:id><gtr:title>Characterising T-cell reconstitution in the first 14 days after stem cell transplantation</gtr:title><gtr:parentPublicationTitle>BONE MARROW TRANSPLANTATION</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/932f1f4821b1892cfe4b41977c4a3bbb"><gtr:id>932f1f4821b1892cfe4b41977c4a3bbb</gtr:id><gtr:otherNames>Inman C.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0268-3369</gtr:issn><gtr:outcomeId>EAm8pyAJrYQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A2ECE74-BE93-477C-BE98-B2CB76204EC9</gtr:id><gtr:title>The presence of CD8+CCR7+T-cells at day 14 post allogeneic stem cell transplant predisposes patients to acute graft versus host disease</gtr:title><gtr:parentPublicationTitle>IMMUNOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e30f6816618b99fde635d83ef2898f83"><gtr:id>e30f6816618b99fde635d83ef2898f83</gtr:id><gtr:otherNames>Croudace J. E.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>MPR5CJui3qj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>02C0F26C-11B4-40B2-9D04-A504B38B7A9A</gtr:id><gtr:title>The number of CD56NK cells in the graft has a major impact on risk of disease relapse following allo-HSCT.</gtr:title><gtr:parentPublicationTitle>Blood advances</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63150c8d07faaf32618aa4ddb576702e"><gtr:id>63150c8d07faaf32618aa4ddb576702e</gtr:id><gtr:otherNames>Maggs L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2473-9529</gtr:issn><gtr:outcomeId>5aa04af963c6c3.86431798</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F7652098-7A4E-4480-AC7F-062483DB2EFA</gtr:id><gtr:title>Contrasting patterns of natural killer and T cell reconstitution in the first 4 weeks following allogeneic haemopoietic stem cell transplantation</gtr:title><gtr:parentPublicationTitle>IMMUNOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69381117807a46099739f96d27c195f5"><gtr:id>69381117807a46099739f96d27c195f5</gtr:id><gtr:otherNames>Chan Y. L. T.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>qEtJ9nTYTpe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A9D08EED-AD48-41C2-A0D9-DE693F8D24B4</gtr:id><gtr:title>R-CHOP Alone For Rituximab Naive Transformed Follicular Lymphoma Has An Excellent Outcome</gtr:title><gtr:parentPublicationTitle>55th American Society of Haematology Annual Meeting and Exposition</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/654bfb1d6cd73707bb62a307e66c9104"><gtr:id>654bfb1d6cd73707bb62a307e66c9104</gtr:id><gtr:otherNames>Chan, Y L Tracey</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>ju11KfG1zMt</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G110379</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>9A8BEDCC-D902-4C9A-8CCF-C974265EA3FB</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.4  Surveillance and distribution</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>